<DOC>
	<DOCNO>NCT02023112</DOCNO>
	<brief_summary>This Phase 3 , randomize , open-label , multicenter study , enrol non-cirrhotic cirrhotic subject . The purpose study evaluate efficacy safety ABT-450/r/ABT-267 co-administered weight-based RBV 12 16 week adult chronic HCV genotype 2-infected treatment-na√Øve interferon ( IFN ) treatment-experienced subject without compensated cirrhosis .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety ABT-450/Ritonavir/ABT- 267 ( ABT-450/r/ABT-267 ) Japanese Adults With Genotype 2 Chronic Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Chronic HCVinfection prior study enrollment Screening laboratory result indicate HCV genotype 2 infection Subject plasma HCV ribonucleic acid ( RNA ) level great 10,000 IU/mL Screening Voluntarily sign inform consent Coinfection Hepatitis B Virus ( HBV ) , human immunodeficiency virus ( HIV ) HCV genotype genotype 2 Prior therapy direct act antiviral agent treatment HCV , include telaprevir , simeprevir boceprevir Any cause liver disease chronic HCVinfection , include limited following : hemochromatosis ; alpha1 antitrypsin deficiency ; Wilson 's disease ; autoimmune hepatitis ; alcoholic liver disease ; drugrelated liver disease Clinically significant laboratory abnormality Uncontrolled clinically significant disease , disorder medical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Japanese</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Treatment naive</keyword>
	<keyword>Treatment experience</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Ombitasvir</keyword>
	<keyword>Paritaprevir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>VIEKIRAX Combination Tablets</keyword>
</DOC>